INT311230

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.38
First Reported 2010
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 6
Total Number 6
Disease Relevance 3.20
Pain Relevance 0.45

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

small molecule metabolic process (GLP1R) plasma membrane (GLP1R) signal transducer activity (GLP1R)
Anatomy Link Frequency
nervous system 2
beta cell 1
GLP1R (Homo sapiens)
Pain Link Frequency Relevance Heat
agonist 115 100.00 Very High Very High Very High
adenocard 5 31.52 Quite Low
tolerance 5 21.04 Low Low
headache 12 5.00 Very Low Very Low Very Low
Central nervous system 5 5.00 Very Low Very Low Very Low
Arthritis 5 5.00 Very Low Very Low Very Low
nud 5 5.00 Very Low Very Low Very Low
cINOD 1 5.00 Very Low Very Low Very Low
antagonist 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Diabetes Mellitus 225 99.84 Very High Very High Very High
Disease 19 96.52 Very High Very High Very High
Hyperglycemia 5 93.24 High High
Disease Progression 26 93.20 High High
Insulin Resistance 7 86.72 High High
Hypoglycemia 47 68.24 Quite High
Renal Failure 10 63.60 Quite High
Natriuresis 5 61.68 Quite High
Weight Loss 40 60.32 Quite High
Renal Insufficiency 20 54.84 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Recently, animal and human studies showed a positive influence of GLP-1 or GLP-1 receptor agonists on the cardiovascular system and on the nervous system, describing neuroprotective effects [17, 95–99].
Regulation (influence) of GLP-1 in nervous system associated with agonist
1) Confidence 0.38 Published 2010 Journal Pediatr Nephrol Section Body Doc Link PMC2874027 Disease Relevance 0.54 Pain Relevance 0.15
Recently, animal and human studies showed a positive influence of GLP-1 or GLP-1 receptor agonists on the cardiovascular system and on the nervous system, describing neuroprotective effects [17, 95–99].
Regulation (influence) of GLP-1 receptor in nervous system associated with agonist
2) Confidence 0.38 Published 2010 Journal Pediatr Nephrol Section Body Doc Link PMC2874027 Disease Relevance 0.54 Pain Relevance 0.15
These comprise the injectable GLP-1 receptor agonists solely acting on the GLP-1 receptor on the one hand and orally active dipeptidyl-peptidase inhibitors (DPP-4 inhibitors) raising endogenous GLP-1 and other hormone levels by inhibiting the degrading enzyme DPP-4.
Regulation (acting) of GLP-1 receptor associated with agonist
3) Confidence 0.23 Published 2010 Journal Pediatr Nephrol Section Abstract Doc Link PMC2874027 Disease Relevance 0.31 Pain Relevance 0.08
Preclinical and animal studies should be undertaken to clarify the potential influence of GLP-1 on beta cell mass in type 1 diabetes and on possible alterations of the autoimmune process.
Regulation (influence) of GLP-1 in beta cell associated with diabetes mellitus
4) Confidence 0.23 Published 2010 Journal Pediatr Nephrol Section Body Doc Link PMC2874027 Disease Relevance 0.71 Pain Relevance 0
These comprise the injectable GLP-1 receptor agonists solely acting on the GLP-1 receptor on the one hand and orally active dipeptidyl-peptidase inhibitors (DPP-4 inhibitors) raising endogenous GLP-1 and other hormone levels by inhibiting the degrading enzyme DPP-4.
Regulation (acting) of GLP-1 receptor associated with agonist
5) Confidence 0.23 Published 2010 Journal Pediatr Nephrol Section Abstract Doc Link PMC2874027 Disease Relevance 0.31 Pain Relevance 0.08
The potential of GLP-1 as a therapy target in type 2 diabetes has gained increasing attention in recent years.
Regulation (target) of GLP-1 associated with diabetes mellitus
6) Confidence 0.19 Published 2010 Journal British Journal of Clinical Pharmacology Section Body Doc Link PMC2997321 Disease Relevance 0.80 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox